Conquering Diseases

Study Of An Investigational Drug For Hidradenitis Suppurativa

Description

Seeking people aged 12 and older whose moderate to severre hidradenitis suppurativa hasn't responded to anti-tumor necrosis factor (TNF) therapy for a study of an investigational drug.

Overview

Participants in this study will be randomly selected to get either one of two different doses of the investigational drug or a placebo (looks like the drug but contains no medicine) as a tablet taken daily for 16 weeks. After 16 weeks, participants may be assigned to get either a different dose or a placebo for an additional 20 weeks. After 36 weeks, participants may continue to take the drug for up to 68 weeks. There will be up to 19 study visits over 28 months

What we're hoping for

We are studying if one of two different doses of an investigational drug is the same, better, or worse than placebo (looks like the drug, but contains no medicine) for moderate to severe hidradenitis suppurativa (HS).

Additional Information

ClinicalTrials.gov Identifier: NCT05889182

 Principal Investigator

Sarah  Whitley, MD

UMass Memorial Health

 Study Contact

Dermatology  Research

774-455-4758

DermResearch@umassmed.edu

 Location

UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989